Contrasting 4D Molecular Therapeutics (FDMT) & Its Competitors

4D Molecular Therapeutics (NASDAQ:FDMT) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare 4D Molecular Therapeutics to related businesses based on the strength of its risk, institutional ownership, valuation, analyst recommendations, earnings, profitability and dividends.

Profitability

This table compares 4D Molecular Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%
4D Molecular Therapeutics Competitors	-12,346.73%	-197.60%	-30.56%

Risk and Volatility

4D Molecular Therapeutics has a beta of 2.92, suggesting that its share price is 192% more volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics’ peers have a beta of 1.10, suggesting that their average share price is 10% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for 4D Molecular Therapeutics and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1	0	10	0	2.82
4D Molecular Therapeutics Competitors	9839	15126	45469	1588	2.54

4D Molecular Therapeutics currently has a consensus target price of $30.22, suggesting a potential upside of 142.53%. As a group, “Biotechnology” companies have a potential upside of 98.31%. Given 4D Molecular Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe 4D Molecular Therapeutics is more favorable than its peers.

Valuation and Earnings

This table compares 4D Molecular Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
4D Molecular Therapeutics	$92.01 million	-$140.11 million	-4.74
4D Molecular Therapeutics Competitors	$741.60 million	$14.11 million	-15.43

4D Molecular Therapeutics’ peers have higher revenue and earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 7.9% of 4D Molecular Therapeutics shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

4D Molecular Therapeutics beats its peers on 8 of the 13 factors compared.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.